litlas
Log inCreate account

Steven Coutré

Active 1986–2022

97
Papers
30,539
Citations
80
h-index
97
i10-index

Citations

Citations per year for Steven Coutré1987: 1 citations1988: 5 citations1989: 4 citations1990: 5 citations1991: 2 citations1992: 5 citations1993: 8 citations1994: 14 citations1995: 7 citations1996: 7 citations1997: 11 citations1998: 6 citations1999: 11 citations2000: 11 citations2001: 5 citations2002: 21 citations2003: 60 citations2004: 78 citations2005: 82 citations2006: 73 citations2007: 90 citations2008: 95 citations2009: 94 citations2010: 63 citations2011: 84 citations2012: 115 citations2013: 122 citations2014: 225 citations2015: 374 citations2016: 282 citations2017: 351 citations2018: 404 citations2019: 1,239 citations2020: 1,421 citations2021: 1,361 citations2022: 823 citations2023: 563 citations2024: 923 citations2025: 350 citations2026: 14 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,586 citing papers, 29.2% of this breakdownChina: 640 citing papers, 7.2% of this breakdownGermany: 634 citing papers, 7.2% of this breakdownUnited Kingdom: 612 citing papers, 6.9% of this breakdownItaly: 542 citing papers, 6.1% of this breakdownFrance: 401 citing papers, 4.5% of this breakdownAustralia: 305 citing papers, 3.4% of this breakdownSpain: 303 citing papers, 3.4% of this breakdownCanada: 252 citing papers, 2.8% of this breakdownSwitzerland: 219 citing papers, 2.5% of this breakdownNetherlands: 200 citing papers, 2.3% of this breakdownSweden: 163 citing papers, 1.8% of this breakdown
0%29.2%Other 22.7%

Institutions

Fields

  • Medicine73.3%
  • Biochemistry, Genetics and Molecular Biology17.2%
  • Immunology and Microbiology6.2%
  • Pharmacology, Toxicology and Pharmaceutics0.8%
  • Chemistry0.8%
  • Computer Science0.4%
  • Other1.3%

Topics

  • Chronic Lymphocytic Leukemia Research13.5%
  • Lymphoma Diagnosis and Treatment7.9%
  • Acute Myeloid Leukemia Research5.9%
  • Chronic Myeloid Leukemia Treatments5.8%
  • Acute Lymphoblastic Leukemia research3.5%
  • Immunodeficiency and Autoimmune Disorders3.2%
  • Other60.2%

Coauthors

All papers

Open in search
  1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

    Authors: Jan A. Burger, Alessandra Tedeschi, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Osnat Bairey, Peter Hillmen, Nancy L. Bartlett, Jianyong Li, David Simpson, Sebastian Grosicki, Stephen Devereux, Helen O. McCarthy, Steven Coutré, Hang Quach, Gianluca Gaïdano, Zvenyslava Maslyak, Don A. Stevens, Ann Janssens, Fritz Offner, Jiřı́ Mayer, Michael O’Dwyer, Andrzej Hellmann, Anna Schuh, Tanya Siddiqi, Aaron Polliack, Constantine S. Tam, Deepali Suri, Mei Cheng, Fong Clow, Lori Styles, Danelle F. James, Thomas J. Kipps - New England Journal of Medicine 2015 cited by 1,562

  2. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Gilles Salles, William G. Wierda, Raquel Izumi, Veerendra Munugalavadla, Priti Patel, Min Hui Wang, Sofia Wong, John C. Byrd - The Lancet 2020 cited by 612

  3. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

    Authors: Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steven Coutré, Claire Dearden, Sebastian Grosicki, Helen O. McCarthy, Jianyong Li, Fritz Offner, Carol Moreno, Cathy Zhou, Emily Hsu, Anita Szőke, Thomas J. Kipps, Paolo Ghia - Blood Advances 2022 cited by 269

  4. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Authors: Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Steven Coutré, Arti Hurria, Jennifer R. Brown, Gerard Lozanski, James S. Blachly, Hatice Gülçin Özer, Brittny Major‐Elechi, Briant Fruth, Sreenivasa Nattam, Richard A. Larson, Harry P. Erba, Mark R. Litzow, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Scott E. Smith, Richard M. Stone, Sumithra J. Mandrekar, John C. Byrd - New England Journal of Medicine 2018 cited by 952

  5. Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien - New England Journal of Medicine 2013 cited by 2,249

  6. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Authors: Tait D. Shanafelt, Xin V. Wang, Neil E. Kay, Curtis A. Hanson, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong C. Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman - New England Journal of Medicine 2019 cited by 738

  7. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

    Authors: Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong Christine Zhang, Steven Coutré, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Neil E. Kay - Blood 2022 cited by 237

  8. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia

    Authors: John C. Byrd, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Neil E. Kay, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Steve Devereux, Paul M. Barr, Richard R. Furman, Thomas J. Kipps, Florence Cymbalista, Christopher Pocock, Patrick Thornton, Federico Caligaris‐Cappio, Tadeusz Robak, Julio Delgado, Stephen J. Schuster, Marco Montillo, Anna Schuh, Sven de Vos, Devinder Gill, Adrian Bloor, Claire Dearden, Carol Moreno, Jeffrey J. Jones, Alvina D. Chu, Maria Fardis, Jesse McGreivy, Fong Clow, Danelle F. James, Peter Hillmen - New England Journal of Medicine 2014 cited by 1,617

  9. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

    Authors: Talha Munir, Jennifer R. Brown, Susan O’Brien, Jacqueline C. Barrientos, Paul M. Barr, Nishitha Reddy, Steven Coutré, Constantine S. Tam, Stephen P. Mulligan, Ulrich Jaeger, Thomas J. Kipps, Carol Moreno, Marco Montillo, Jan A. Burger, John C. Byrd, Peter Hillmen, Sandra Dai, Anita Szőke, James P. Dean, Jennifer A. Woyach - American Journal of Hematology 2019 cited by 473

  10. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

    Authors: Jeff P. Sharman, Miklós Egyed, Wojciech Jurczak, Alan P Skarbnik, John M. Pagel, Ian W. Flinn, Manali Kamdar, Talha Munir, Renata Walewska, Gillian Corbett, Laura Fogliatto, Yair Herishanu, Versha Banerji, Steven Coutré, George Follows, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, Florence Cymbalista, Jennifer A. Woyach, Emmanuelle Ferrant, William G. Wierda, Veerendra Munugalavadla, Ting Yu, Min Hui Wang, John C. Byrd - Leukemia 2022 cited by 200

  11. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

    Authors: Richard R. Furman, Jeff P. Sharman, Steven Coutré, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Stephan Stilgenbauer, Paula Cramer, Maria Aiello, Dave M. Johnson, Langdon L. Miller, Daniel Li, Thomas M. Jahn, Roger Dansey, Michael Hallek, Susan O’Brien - New England Journal of Medicine 2014 cited by 1,684

  12. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Steven Coutré, John F. Seymour, Talha Munir, Soham D. Puvvada, Clemens‐Martin Wendtner, Andrew W. Roberts, Wojciech Jurczak, Stephen P. Mulligan, Sebastian Böttcher, Mehrdad Mobasher, Ming Zhu, Monali Desai, Brenda Chyla, Maria Verdugo, Sari H. Enschede, Elisa Cerri, Rod Humerickhouse, Gary Gordon, Michael Hallek, William G. Wierda - The Lancet Oncology 2016 cited by 796

  13. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

    Authors: Jan A. Burger, Paul M. Barr, Tadeusz Robak, Carolyn Owen, Paolo Ghia, Alessandra Tedeschi, Osnat Bairey, Peter Hillmen, Steven Coutré, Stephen Devereux, Sebastian Grosicki, Helen O. McCarthy, David Simpson, Fritz Offner, Carol Moreno, Sandra Dai, Indu Lal, James P. Dean, Thomas J. Kipps - Leukemia 2019 cited by 463

  14. Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia

    Authors: Esther Benamu, Kiran Gajurel, Jill N. Anderson, Tullia Lieb, Carlos A. Gómez, Hon Seng, Romielle Aquino, Desiree Hollemon, David K. Hong, Timothy A. Blauwkamp, Mickey Kertesz, Lily Blair, Paul L. Bollyky, Bruno C. Medeiros, Steven Coutré, Simona Zompì, José G. Montoya, Stan Deresinski - Clinical Infectious Diseases 2021 cited by 126

  15. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

    Authors: Jeffrey A. Jones, Anthony R. Mato, William G. Wierda, Matthew S. Davids, Michael Y. Choi, Bruce D. Cheson, Richard R. Furman, Nicole Lamanna, Paul M. Barr, Lang Zhou, Brenda Chyla, Ahmed Hamed Salem, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Steven Coutré, Jennifer A. Woyach, John C. Byrd - The Lancet Oncology 2017 cited by 378

  16. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial

    Authors: Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Peter Hillmen, John F. Seymour, Steven Coutré, Wojciech Jurczak, Stephen P. Mulligan, Anna Schuh, Sarit Assouline, Clemens‐Martin Wendtner, Andrew W. Roberts, Matthew S. Davids, Johannes Bloehdorn, Talha Munir, Sebastian Böttcher, Lang Zhou, Ahmed Hamed Salem, Monali Desai, Brenda Chyla, Jennifer A. Arzt, Su Young Kim, Maria Verdugo, Gary Gordon, Michael Hallek, William G. Wierda - Journal of Clinical Oncology 2018 cited by 313

  17. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

    Authors: Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale L. Bixby, Steven Coutré, Marcos de Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan A. Jacoby, Jeffrey E. Lancet, Thomas W. LeBlanc, Gabriel N. Mannis, Guido Marcucci, Michael G. Martin, Alice S. Mims, Margaret O’Donnell, Rebecca L. Olin, Deniz Peker, Alexander E. Perl, Daniel A. Pollyea, Keith W. Pratz, Thomas Prébet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew J. Wieduwilt, Kristina M. Gregory, OCN, Lydia J. Hammond, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2019 cited by 424

  18. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Weiqiang Zhao, Nyla A. Heerema, Ying Luan, Emily A. Liu, James P. Dean, Susan O’Brien - Clinical Cancer Research 2020 cited by 183

  19. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

    Authors: Margaret O’Donnell, Martin S. Tallman, Camille N. Abboud, Jessica K. Altman, Frederick R. Appelbaum, Daniel A. Arber, Vijaya Raj Bhatt, Dale L. Bixby, William Blum, Steven Coutré, Marcos de Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Steven D. Gore, Aric C. Hall, Patricia Kropf, Jeffrey E. Lancet, Lori J. Maness, Guido Marcucci, Michael G. Martin, Joseph O. Moore, Rebecca L. Olin, Deniz Peker, Daniel A. Pollyea, Keith W. Pratz, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Eunice S. Wang, Matthew J. Wieduwilt, Kristina M. Gregory, Ndiya Ogba - Journal of the National Comprehensive Cancer Network 2017 cited by 655

  20. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    Authors: Jennifer R. Brown, Javid J. Moslehi, Susan O’Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutré, Marie‐Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael M. Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, Jan A. Burger - Haematologica 2017 cited by 258

  21. Acute Lymphoblastic Leukemia, Version 2.2015

    Authors: Joseph Alvarnas, Patrick A. Brown, Patricia Aoun, Karen K. Ballen, Stefan K. Barta, Uma Borate, Michael W. Boyer, Patrick W. Burke, Ryan D. Cassaday, Januario E. Castro, Peter F. Coccia, Steven Coutré, Lloyd E. Damon, Daniel J. DeAngelo, Dan Douer, Olga Frankfurt, John P. Greer, Robert A. Johnson, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary M. Kupfer, Mark R. Litzow, Arthur Liu, Arati V. Rao, Bijal Shah, Geoffrey L. Uy, Eunice S. Wang, Andrew D. Zelenetz, Kristina M. Gregory, Courtney Smith - Journal of the National Comprehensive Cancer Network 2015 cited by 245

  22. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables

    Authors: Andrew W. Roberts, Shuo Ma, Thomas J. Kipps, Steven Coutré, Matthew S. Davids, Barbara Eichhorst, Michael Hallek, John C. Byrd, Kathryn Humphrey, Lang Zhou, Brenda Chyla, Jacqueline Nielsen, Jalaja Potluri, Su Young Kim, Maria Verdugo, Stephan Stilgenbauer, William G. Wierda, John F. Seymour - Blood 2019 cited by 175

  23. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

    Authors: Jeff P. Sharman, Steven Coutré, Richard R. Furman, Bruce D. Cheson, John M. Pagel, Peter Hillmen, Jacqueline C. Barrientos, Andrew D. Zelenetz, Thomas J. Kipps, Ian W. Flinn, Paolo Ghia, Herbert Eradat, Thomas J. Ervin, Nicole Lamanna, Bertrand Coiffier, Andrew R. Pettitt, Shuo Ma, Eugen Tausch, Paula Cramer, Julie Huang, Siddhartha Mitra, Michael Hallek, Susan O’Brien, Stephan Stilgenbauer - Journal of Clinical Oncology 2019 cited by 221

  24. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

    Authors: John C. Byrd, Richard R. Furman, Steven Coutré, Jan A. Burger, Kristie A. Blum, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Yun Shaw, Elizabeth Bilotti, Cathy Zhou, Danelle F. James, Susan O’Brien - Blood 2015 cited by 656